Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors

被引:29
作者
Seethapathy, Harish [1 ]
Rusibamayila, Nifasha [1 ]
Chute, Donald F. [1 ]
Lee, Meghan [2 ]
Strohbehn, Ian [2 ]
Zubiri, Leyre [3 ]
Faje, Alexander T. [4 ]
Reynolds, Kerry L. [3 ]
Jhaveri, Kenar D. [5 ]
Sise, Meghan E. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Internal Med, Div Nephrol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Internal Med, Gastrointestinal Unit, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Internal Med, Div Hematol & Oncol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Internal Med, Div Endocrinol, Boston, MA 02114 USA
[5] Donald & Barbara Zucker Sch Med Hofstra Northwell, Div Kidney Dis & Hypertens, Great Neck, NY USA
基金
美国国家卫生研究院;
关键词
electrolytes; hypokalemia; hypophosphatemia; hyponatremia; hypophysitis; immune checkpoint inhibitor; CELL LUNG-CANCER; ACUTE KIDNEY INJURY; PROGNOSTIC-FACTORS; DISORDERS;
D O I
10.1093/ndt/gfaa272
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Hyponatremia due to endocrinopathies such as adrenal insufficiency and hypothyroidism has been reported in patients receiving immune checkpoint inhibitors (ICIs). We determined the risk and predictors of hyponatremia and other electrolyte abnormalities in a 'real-world' sample of patients receiving ICIs to treat advanced malignancies. Methods. This was a retrospective observational study of all patients who received ICIs from a single cancer center between 2011 and 2018. Patients were followed for 12 months after initiation of ICIs or until death. Common Terminology for Cancer Adverse Events version 5.0 criteria were used to grade the severity of hyponatremia and other electrolyte abnormalities. The predictors of severe (Grade 3 or 4) hyponatremia were determined using a multivariable logistic regression model. The etiology of Grade 3 or 4 hyponatremia was determined by chart review. Results. A total of 2458 patients were included. Their average age was 64 years [standard deviation (SD) 13], 58% were male and 90% were white. In the first year after starting ICIs, 62% experienced hyponatremia (sodium <134 mEq/L) and 136 (6%) experienced severe hyponatremia (<124 mEq/L). Severe hyponatremia occurred on average 164 days (SD 100) after drug initiation. Only nine cases of severe hyponatremia were due to endocrinopathies (0.3% overall incidence). Risk factors for severe hyponatremia included ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor) use, diuretic use and non-White race. Other severe electrolyte abnormalities were also commonly observed: severe hypokalemia (potassium <3.0 mEq/L) occurred in 6%, severe hyperkalemia (potassium >= 6.1 mEq/L) occurred in 0.6%, severe hypophosphatemia (phosphorus <2 mg/dL) occurred in 17% and severe hypocalcemia (corrected calcium <7.0 mg/dL) occurred in 0.2%. Conclusions. Hyponatremia is common in cancer patients receiving ICIs. However, endocrinopathies are an uncommon cause of severe hyponatremia.
引用
收藏
页码:2241 / 2247
页数:7
相关论文
共 28 条
  • [1] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
    Barroso-Sousa, Romualdo
    Barry, William T.
    Garrido-Castro, Ana C.
    Hodi, F. Stephen
    Min, Le
    Krop, Ian E.
    Tolaney, Sara M.
    [J]. JAMA ONCOLOGY, 2018, 4 (02) : 173 - 182
  • [2] Cost of illness of hyponatremia in the United States
    Boscoe A.
    Paramore C.
    Verbalis J.G.
    [J]. Cost Effectiveness and Resource Allocation, 4 (1)
  • [3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    Brahmer, Julie R.
    Drake, Charles G.
    Wollner, Ira
    Powderly, John D.
    Picus, Joel
    Sharfman, William H.
    Stankevich, Elizabeth
    Pons, Alice
    Salay, Theresa M.
    McMiller, Tracee L.
    Gilson, Marta M.
    Wang, Changyu
    Selby, Mark
    Taube, Janis M.
    Anders, Robert
    Chen, Lieping
    Korman, Alan J.
    Pardoll, Drew M.
    Lowy, Israel
    Topalian, Suzanne L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3167 - 3175
  • [4] Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis
    Cantini, Luca
    Merloni, Filippo
    Rinaldi, Silvia
    Lenci, Edoardo
    Marcantognini, Giulia
    Meletani, Tania
    Fiordoliva, Ilaria
    Morgese, Francesca
    Torniai, Mariangela
    Ricci, Giulia
    Giampieri, Riccardo
    Berardi, Rossana
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 151
  • [5] Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
    Cortazar, Frank B.
    Kibbelaar, Zoe A.
    Glezerman, Ilya G.
    Abudayyeh, Ala
    Mamlouk, Omar
    Motwani, Shveta S.
    Murakami, Naoka
    Herrmann, Sandra M.
    Manohar, Sandhya
    Shirali, Anushree C.
    Kitchlu, Abhijat
    Shirazian, Shayan
    Assal, Amer
    Vijayan, Anitha
    Renaghan, Amanda DeMauro
    Ortiz-Melo, David, I
    Rangarajan, Sunil
    Malik, A. Bilal
    Hogan, Jonathan J.
    Dinh, Alex R.
    Shin, Daniel Sanghoon
    Marrone, Kristen A.
    Mithani, Zain
    Johnson, Douglas B.
    Hosseini, Afrooz
    Uprety, Deekchha
    Sharma, Shreyak
    Gupta, Shruti
    Reynolds, Kerry L.
    Sise, Meghan E.
    Leaf, David E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (02): : 435 - 446
  • [6] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
    Cortazar, Frank B.
    Marrone, Kristen A.
    Troxell, Megan L.
    Ralto, Kenneth M.
    Hoenig, Melanie P.
    Brahmer, Julie R.
    Le, Dung T.
    Lipson, Evan J.
    Glezerman, Ilya G.
    Wolchok, Jedd
    Cornell, Lynn D.
    Feldman, Paul
    Stokes, Michael B.
    Zapata, Sarah A.
    Hodi, F. Stephen
    Ott, Patrick A.
    Yamashita, Michifumi
    Leaf, David E.
    [J]. KIDNEY INTERNATIONAL, 2016, 90 (03) : 638 - 647
  • [7] Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy
    Doshi, Kartik H.
    Shriyan, Bharati
    Nookala, Manjunath K.
    Kannan, Sadhana
    Joshi, Amit
    Noronha, Vanita
    Gota, Vikram
    Prabhash, Kumar
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (05) : 1049 - 1053
  • [8] Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
    Faje, Alexander
    Reynolds, Kerry
    Zubiri, Leyre
    Lawrence, Donald
    Coher, Justine, V
    Sullivan, Ryan J.
    Nachtigall, Lisa
    Tritos, Nicholas
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (03) : 211 - 219
  • [9] Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
    Haslam, Alyson
    Gill, Jennifer
    Prasad, Vinay
    [J]. JAMA NETWORK OPEN, 2020, 3 (03)
  • [10] Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]